Brain natriuretic peptide (BNP), left ventricular (LV) systolic function, and mitral filling pattern (MFP) are prognostic indicators in patients with heart failure (HF). This study evaluated the potential role of E/Ea for predicting cardiovascular (CV) events in patients with suspected HF. This non-invasive measure of LV filling pressure has been shown to predict outcome in more advanced HF, but not in mild HF in the community.
Diastolic echocardiographic measurements can provide important prognostic information in patients with established heart failure (HF), especially the differentiation of restrictive filling pattern (RFP) from non-restrictive patterns. 1 Within the non-restrictive group, further differentiation of the patients with pseudonormal filling reveals a group at intermediate risk. 2, 3 Pulsed wave tissue Doppler imaging (TDI) is now commonly used to assess diastolic function. In particular, the ratio of mitral E velocity to annular E velocity (E/Ea) is related to filling pressure 4 -6 and tissue Doppler measurements have been linked to cardiovascular outcome. 6 -13 Similarly, neurohormones have been used to predict outcome in HF patients. Elevated B-type or brain natriuretic peptide (BNP) level is associated with higher mortality 7 -12 and hospitalization rates 11, 13 and worsening HF. 14 -16 Most of these prognostic studies were performed in cohorts of patients with established HF and included patients with severe chronic disease, such as patients referred to a transplant clinic, admitted to hospital for exacerbation of symptoms, or attending specialist HF clinics. Very little data exist regarding the prognostic role of echocardiography in the community, despite the fact that echocardiography is increasingly being utilized for diagnosis of HF in community-based patients. 17, 18 Both BNP and echocardiography have been used to screen asymptomatic elderly and communitybased individuals for the presence of LV dysfunction and when elevated BNP levels and/or systolic dysfunction are identified, both are associated with worse outcome. 19 -23 The Natriuretic Peptides in the Community (NPC) study 24 was designed to prospectively evaluate the role of NT-proBNP in the diagnosis of HF in elderly community-based patients. The aim of this substudy was to prospectively evaluate the prognostic role of echocardiography and NT proBNP measurements for predicting subsequent hospitalization in these patients.
Methods Subjects
This substudy includes 228 patients from a randomized clinical trial evaluating the utility of NT-proBNP in the diagnosis of HF in primary care, which recruited 305 symptomatic patients from primary care practices. The trial methods and results have been described elsewhere. 24 Patients who presented to their general practitioner with signs and symptoms of HF (dyspnoea or oedema) were eligible for this study. General practitioners were responsible for the identification of referral of eligible patients who then attended a hospital study visit where, after providing written informed consent, a cardiological assessment, electrocardiography, chest radiography, blood collection for NT-proBNP measurement, and transthoracic echocardiography were performed. This substudy includes all those patients with complete diastolic evaluation including TDI (n ¼ 228). It is smaller than the total cohort (n ¼ 305) because this technology was not available at the commencement of the main study. The study was approved by the Auckland Ethics Committee and all patients provided written informed consent.
Panel standard diagnosis of heart failure
The diagnosis of HF was made by an expert panel of three cardiologists and one general physician independently of other study personnel and without the knowledge of the NT-proBNP result. The panel reviewed all clinical data for each patient including ECG, chest radiograph, and echocardiograph, but not NT-proBNP results in order to determine whether the clinical syndrome of HF was present using the European Society of Cardiology Working Group on Heart Failure diagnostic criteria. 25 To meet the case definition of HF, patients were required to have appropriate symptoms (dyspnoea or oedema) with clinical signs of pulmonary or peripheral congestion in the presence of an underlying abnormality of cardiac structure and function. If doubt remained, response to treatment was considered.
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Statistical analysis
Comparisons between groups for continuous normally distributed variables were made using Student's t-test and analysis of variance and non-parametric continuous data were analysed using Wilcoxon and Kruskall -Wallace tests, where appropriate. Differences between categorical variables were assessed using x 2 analysis. ANOVA was used to determine between group differences when there were more than two groups and post hoc Tukey's test for within group differences. A P-value , 0.05 was accepted as indicating significance.
Time to first CV death/hospitalization analysis
The primary endpoint was a composite of cardiovascular death and/or hospitalization. Medical charts and general practice computer databases were reviewed 18 months after recruitment into the study to collect data regarding each patient's vital status and number of and reason for hospitalizations. Stratified survival analysis was performed using the Kaplan-Meier method. Where more than two categorical groups were tested (e.g. NT-proBNP level or diastolic filling pattern) x 2 was used to test overall significance. All tests were twotailed and 5% significance level was maintained throughout. Procedures of the statistical analysis system (SAS) were employed in these analyses (SAS Institute, Cary, NC, USA).
Analysis by NT-proBNP level
The survival analyses were performed in different patients subgroups based upon the NT-proBNP level: less then 50 pmol/L (HF diagnosis unlikely), 50 -150 pmol/L (HF diagnosis uncertain), and .150 pmol/L (HF diagnosis likely). 28 This was done in order to compare the role of echocardiography within these groups of patients and to reflect the likely clinical scenarios in which physicians might use both echocardiography and NT-proBNP. These equate to 423 pg/mL (50 pmol/L) and 1269 pg/mL (150 pmol/L) ( Table 1) .
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Results
Baseline characteristics
The mean age of the group was 70 years (range 40 -95 years), 65% were female, 52% had a history of hypertension, 15% had type 2 diabetes, 14% prior acute myocardial infarction, and 14% reported chronic airways disease or asthma. NT-proBNP was elevated and baseline echocardiography revealed a group of patients with mildly dilated hearts, no significant systolic dysfunction, but with evidence of some advanced diastolic filling abnormalities and elevated filling pressure ( Table 2 ). This group were not significantly different to the main clinical trial cohort ( 
Time to first CV death/hospitalization
During the18 month follow-up period, 26 (11.4%) patients experienced a first CV event (20 hospitalizations and 6 deaths). The median time to first CV event was 339 (range 0-545) days. Time to first event analysis is presented by NT-proBNP level, ejection fraction, diastolic filling pattern, and E/Ea (Figure 1 ). Vital status was unavailable for 13 patients.
NT-proBrain natriuretic peptide
There was a tiered relationship between hospitalization and NT-proBNP level (P , 0.0001). NT-proBNP ! 150 mmol/L was associated with worse outcome (10 CV events, event rate 26%) than NT-proBNP , 150 mmol/L (16 CV events, event rate 8.5%) hazard ratio 4.1 (95% CI: 1.9,9.1, P ¼ 0.0005). NT-proBNP ! 50 mmol/L was associated with worse outcome (20 CV events, event rate 19.6%) than NT-proBNP , 50 mmol/L (6 CV events, event rate 5.2%); hazard ratio 3.8 (95% CI: 1.5,9.4, P ¼ 0.004)( Figure 1A ).
Ejection fraction
Thirty-three subjects had an EF 45% and this was associated with higher rates of CV hospitalization or death (18%) compared to patients with EF . 45% (10%); hazard ratio 2.0 (95% CI: 0.8,5.1, P ¼ 0.13, log-rank P ¼ 0.098) ( Figure 1B ).
Diastolic filling pattern
Eleven subjects (5.5%) displayed RFP at baseline and these patients had higher rates of CV events (27%) compared to patients with non-RFP (10%); hazard ratio 5.0 (95% CI: 1. to the restrictive filling group (P ¼ 0.008) but no difference was seen between the pseudonormal filling and abnormal relaxation groups (overall difference P ¼ 0.0089) ( Figure 1C ).
E/Ea ratio
E/Ea was 8 in 77 (34%) subjects, between 9 and 15 in 112 (49%) subjects, and .15 in 39 (17%) subjects. There were 5 CV events in the group with E/Ea 8 (6.4% event rate), 11 in the group with E/Ea 9-15 (event rate 9.8%), and 10 in the group with E/Ea . 15 (event rate 10%) (x 2 ¼ 0.0069). The hazard ratio for E/Ea ! 15 was 3.6 (95% CI: 1.6,8.0, P ¼ 0.0015) and for E/Ea ! 8 was 2.2 (95% CI: 0.84,5.9, P ¼ 0.11) ( Figure 1D ). (consistent with advanced diastolic filling abnormalities and significantly elevated filling pressure) ( Table 4) .
Two-tiered approach with NT-proBNP and E/Ea
When the groups were divided on the basis of NT-proBNP level (, or . 50 pmol/L), and then the patients with elevated NT-proBNP were divided into two groups on the basis of E/Ea (, or . 15), there was a significant difference in the time to first CV event (P , 0.0001). The low NT-proBNP group (n ¼ 116) had the same outcome as the high NT-proBNP/low E/Ea group (n ¼ 73), but both had significantly lower CV event rates than the high NT-proBNP/high E/Ea group (n ¼ 39) (Figure 2 ).
Discussion
In this study, E/Ea, an echocardiographic surrogate of LA pressure, was closely linked to future cardiovascular events (death or hospitalization) in community patients with symptoms of breathlessness and/or oedema. Although other studies have demonstrated the link between diastolic parameters and outcome in established HF, 3,6,29 -33 we believe this may be the first study to do so in this particular patient cohort. Although restrictive filling was predictive of outcome, no difference between the pseudonormal and abnormal filling groups was observed. However, E/Ea identified three distinct groups each with associated and incremental eventfree survival rates.
Other traditional echocardiographic variables, such as EF and mitral filling pattern, as well as NT-proBNP also predicted hospitalization, but in multivariable analysis, only E:Ea and age predicted CV events. The prognostic role of NT-proBNP and BNP in primary care patients with suspected HF has been previously demonstrated. 34, 35 The current study has extended these findings and Figure 2 Time to first hospitalization using two-step approach BNP, diastolic filling, dyspnoea and prognosis further differentiated the combined role of neurohormonal and echocardiographic assessment. When the event rates were compared across the patient cohort divided on the basis of neurohormone level, both E:Ea and NT-proBNP were independent predictors, depending upon the neurohormone level. These results support a complementary role for the two techniques. When used in a pragmatic, two-tiered approach (NT-proBNP assay followed by E/Ea), the prognostic role of both may be optimized. In this setting, the addition of E/Ea identified two sub-groups of patients within the group with elevated NT-proBNP levelpatients with low E/Ea had similar outcome as patients with normal NT-proBNP and patients with elevated E/Ea with higher hospitalization. The subjects with the highest E/Ea had much higher NT-proBNP levels and also more systolic dysfunction. Echocardiographic measurements and neurohormone levels should not be considered independently as they are almost certainly inter-related and indeed demonstrated in patients with symptomatic systolic HF. 36 E/Ea correlates with filling pressures in several studies 4 -6,37,38 and has been previously linked to prognosis in patients with established cardiovascular disease 39, 40 and has been used in both atrial fibrillation 41 and supraventricular tachycardia. 37 In the current study, E/Ea even predicted CV events in those patients in whom HF was not considered the primary cause of symptoms. E/Ea may have identified a group of patients with elevated filling pressures but without definitive clinical HF. E/Ea is related to left atrial pressure and thus some of the non-HF patients may have had some degree of increased filling pressure. This is supported by the fact that both E/Ea, 4 -6 and deceleration time 41 -47 are both related to left ventricular filling pressure. BNP is also closely correlated with deceleration time. 48, 49 BNP is a marker of haemodynamic stress and it may be that E/Ea is similarly reflective of haemodynamic stress in these patients. In a recently published study performed in patients hospitalized for HF symptoms, a similarly incremental prognostic utility for BNP and E/Ea was demonstrated. 50 The current study is at the other end of the disease spectrum. In a similar cohort of patients, traditional mitral valve and pulmonary venous diastolic parameters did not add significantly to clinical assessment and assessment of systolic function. 38 This study was similar in many ways to our study with the exception that neither BNP nor tissue Doppler measurements were available. Mitral valve filling pattern is a powerful prognostic indicator in patients with advanced HF, but its categorical nature and low prevalence of advanced filling patterns in newly diagnosed HF may render it of limited use in newly diagnosed HF. Since E/Ea is a continuous variable, this may explain its superior prognostic differentiation.
Conclusion
This study has demonstrated the complementary roles of neurohormone assay and echocardiography as predictive markers of CV outcome in symptomatic patients in the community. Both techniques identify different subgroups of patients with different associated prognosis. These data would support a two-step approach that incorporates both NT-proBNP levels with echocardiographic diastolic assessment and may identify those at highest risk of subsequent cardiovascular death or hospitalization.
